The purpose of this study is to evaluate the safety, reactogenicity, and immune response induced by the GlaxoSmithKline Biologicals SA (GSK) Vaccines Institute for Global Health (GVGH) invasive nontyphoidal Salmonella-typhoid conjugate (iNTS-TCV) vaccine in infants with the first dose administered at 6 months of age (MOA) or 6 weeks of age (WOA).
Have signed/thumb-printed, voluntary, informed consent provided for them by their parent/Legally Authorized Representative (LAR) prior to performance of any study-specific procedure.
Be a male or female infant aged 6 months (±2 weeks) or 6 weeks (+2 weeks) of age at the time of the first study vaccination.
Have a parent/LAR, who can and will comply with the requirements of the protocol.
Healthy as established by medical history, clinical examination, and laboratory assessment.
Have had a known infection with STm, SEn or S. Typhi.
Have a history of allergic reactions to any prior vaccination or components of the investigational or control vaccines.
Hypersensitivity to latex.
History of any reaction or hypersensitivity likely to be exacerbated by any component of the study interventions.
14
Treatment groupsSee each treatment group below.